Study (Subjects) Period Outcomes Mammen10 (n = 126) 1 year Morgan8 (n = 127) 2 years Cooper46 (n = 51) 5–7 years Madsen47 (n = 382) 5–15 years Greenberg-TRIBE Consortium48 (n = 131) 5 years Microalbuminuria/proteinuria (10%) GFR 60–90 mL/min/1.73 m2 (38%) GFR >150 mL/min/1.73 m2 (9%) Mortality (10% AKI vs 4.3% no AKI) Increased hospitalizations (stage 3 AKI) Decreased height SDS (stage 3 AKI) No difference in standard CKD assessments (AKI vs no AKI) Increased urinary damage biomarker concentrations in patients with AKI vs no AKI Increased CKD prevalence AKI vs no AKI (5-year HR 3.8 (95% CI 1.4–10.4) Hypertension (10%) Microalbuminuria (8%) GFR